Lysergide tartrate (LSD) vs Mebufotenin (5-MeO-DMT)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
Lysergide tartrate (LSD) · DT120
Developed by Definium Therapeutics
NCT06941844 · Phase 3 · active, not recruiting
Participants were randomized and the study was triple-blinded (participant, investigator, and outcomes assessor) against a placebo comparator, which minimizes bias from expectation effects common in psychedelic trials. The primary endpoint, change in a validated clinical depression severity scale (MADRS) at Week 6, showed a large and statistically significant improvement for the drug versus placebo (p<0.0001), meeting the pre-specified comparison in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: September 2027 · NCT07592689 (registry estimate)
Reported efficacy
Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6): Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. (met)
Result source: NCT06941844
Mebufotenin (5-MeO-DMT) · GH001
Developed by GH Research
NCT05800860 · Phase 2 · completed
This randomized, quadruple-masked, placebo-controlled phase 2 trial assigned 81 patients with treatment-resistant depression to inhaled GH001 (mebufotenin) or placebo. The registered primary endpoint was the change in MADRS depression score from baseline to Day 7. The sponsor reported a placebo-adjusted reduction of 15.5 points at Day 8 (P<0.0001), so the primary endpoint was met. This result comes from a company filing and is not posted on ClinicalTrials.gov, and no power calculation was found.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Mean change in MADRS from Baseline to Day 7: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001) (met)
Result source: NCT05800860
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lysergide tartrate (LSD) | Mebufotenin (5-MeO-DMT) |
|---|---|---|
| MADRS, change (acute) | —Trial running · NCT06941844 | —Not reported |
| CGI-S, change (acute) | —Trial running · NCT06941844 | —Not reported |
| MADRS response | —Trial running · NCT06941844 | —Not reported |
| MADRS remission | —Trial running · NCT06941844 | —Not reported |
| Relapse (% of patients) | —Trial running · NCT06941844 | —Not reported |
MADRS, change (acute)
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Mebufotenin (5-MeO-DMT)
- —Not reported
CGI-S, change (acute)
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Mebufotenin (5-MeO-DMT)
- —Not reported
MADRS response
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Mebufotenin (5-MeO-DMT)
- —Not reported
MADRS remission
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Mebufotenin (5-MeO-DMT)
- —Not reported
Relapse (% of patients)
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Mebufotenin (5-MeO-DMT)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Mebufotenin (5-MeO-DMT)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lysergide tartrate (LSD)'s landscape · Mebufotenin (5-MeO-DMT)'s landscape